NO2019047I1 - ravulizumab - Google Patents

ravulizumab

Info

Publication number: NO2019047I1
Authority: NO; Norway
Prior art keywords: ravulizumab
Prior art date: 2007-12-26

Application number

NO2019047C

Other languages

English (en)

Original Assignee

Xencor Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-26

Filing date

2019-12-19

Publication date

2019-12-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40578856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2019047(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2019-12-19 Application filed by Xencor Inc filed Critical Xencor Inc

2019-12-19 Publication of NO2019047I1 publication Critical patent/NO2019047I1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Zoology (AREA)
Cell Biology (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO2019047C 2007-12-26 2019-12-19 ravulizumab NO2019047I1 (no)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
US1679307P	2007-12-26	2007-12-26
US3135308P	2008-02-25	2008-02-25
US4635308P	2008-04-18	2008-04-18
US5017208P	2008-05-02	2008-05-02
US7977908P	2008-07-10	2008-07-10
US9917808P	2008-09-22	2008-09-22
EP08866130.1A EP2235059B1 (en)	2007-12-26	2008-12-22	Fc variants with altered binding to fcrn
PCT/US2008/088053 WO2009086320A1 (en)	2007-12-26	2008-12-22	Fc variants with altered binding to fcrn

Publications (1)

Publication Number	Publication Date
NO2019047I1 true NO2019047I1 (no)	2019-12-19

Family

ID=40578856

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO2019047C NO2019047I1 (no)	2007-12-26	2019-12-19	ravulizumab

Country Status (23)

Country	Link
US (4)	US20200255502A1 (no)
EP (6)	EP2235059B1 (no)
JP (8)	JP5726534B2 (no)
KR (1)	KR101616758B1 (no)
CN (2)	CN105418762B (no)
AU (7)	AU2008345242B2 (no)
BR (2)	BR122021010656B1 (no)
CA (4)	CA3086659A1 (no)
CY (2)	CY1122019T1 (no)
DK (2)	DK2235059T3 (no)
ES (2)	ES2742268T3 (no)
FR (1)	FR19C1075I1 (no)
HR (2)	HRP20150279T1 (no)
HU (4)	HUE024903T2 (no)
IL (2)	IL206457A (no)
LT (3)	LT2808343T (no)
LU (1)	LUC00142I2 (no)
NO (1)	NO2019047I1 (no)
PL (2)	PL2808343T3 (no)
PT (1)	PT2808343T (no)
RU (3)	RU2529951C2 (no)
SI (2)	SI2808343T1 (no)
WO (1)	WO2009086320A1 (no)

Families Citing this family (195)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7183387B1 (en)	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
US20090010920A1 (en)	2003-03-03	2009-01-08	Xencor, Inc.	Fc Variants Having Decreased Affinity for FcyRIIb
US9714282B2 (en)	2003-09-26	2017-07-25	Xencor, Inc.	Optimized Fc variants and methods for their generation
US8435517B2 (en)	2008-09-17	2013-05-07	Xencor, Inc.	Compositions and methods for treating IgE-mediated disorders
US20150010550A1 (en)	2004-07-15	2015-01-08	Xencor, Inc.	OPTIMIZED Fc VARIANTS
US8802820B2 (en) *	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
US8367805B2 (en)	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
CN102746404B (zh)	2004-11-12	2016-01-20	赞科股份有限公司	对FcRn的结合被改变的Fc变体
WO2007041635A2 (en)	2005-10-03	2007-04-12	Xencor, Inc.	Fc variants with optimized fc receptor binding properties
ES2892925T3 (es)	2006-03-31	2022-02-07	Chugai Pharmaceutical Co Ltd	Métodos para controlar la farmacocinética en sangre de anticuerpos
CL2008002886A1 (es)	2007-09-26	2009-12-04	Chugai Pharmaceutical Co Ltd	Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
EP3127921A1 (en)	2007-09-26	2017-02-08	Chugai Seiyaku Kabushiki Kaisha	Method of modifying isoelectric point of antibody via amino acid substition in cdr
ES2742268T3 (es)	2007-12-26	2020-02-13	Xencor Inc	Variantes de Fc con unión alterada a FcRn
BRPI0911431B8 (pt)	2008-04-11	2021-05-25	Chugai Pharmaceutical Co Ltd	composição farmacêutica compreendendo um antígeno e método para aumentar o número de antígenos que podem ser ligados por um anticorpo
TWI572357B (zh) *	2008-10-14	2017-03-01	建南德克公司	免疫球蛋白變異體及其用途
AU2013203391B2 (en) *	2008-10-14	2016-03-03	Genentech, Inc.	Immunoglobulin variants and uses thereof
WO2011028952A1 (en)	2009-09-02	2011-03-10	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
PL2536745T3 (pl) *	2010-02-19	2017-01-31	Xencor, Inc.	Nowe immunoadhezyny CTLA4-IG
TWI667346B (zh) *	2010-03-30	2019-08-01	中外製藥股份有限公司	促進抗原消失之具有經修飾的FcRn親和力之抗體
EP4501956A2 (en)	2010-03-30	2025-02-05	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecules that promote antigen clearance
WO2012002562A1 (en) *	2010-06-30	2012-01-05	Tokyo University Of Science Educational Foundation Administrative Organization	Modified protein therapeutics
CN103052649B (zh) *	2010-07-29	2015-12-16	Xencor公司	具有修改的等电点的抗体
EA031044B1 (ru)	2010-10-13	2018-11-30	Янссен Байотек, Инк.	Человеческие антитела к онкостатину м и способы их применения
BR112013013354A2 (pt)	2010-11-30	2020-10-06	Chugai Seiyaku Kabushiki Kaisha	molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
SG192945A1 (en)	2011-02-25	2013-09-30	Chugai Pharmaceutical Co Ltd	Fcgriib-specific fc antibody
WO2012132067A1 (ja) *	2011-03-30	2012-10-04	中外製薬株式会社	抗原結合分子の血漿中滞留性と免疫原性を改変する方法
JP5926791B2 (ja)	2011-03-29	2016-05-25	ロシュグリクアートアーゲー	抗体Ｆｃ変種
DK2698431T3 (da) *	2011-03-30	2020-11-30	Chugai Pharmaceutical Co Ltd	Opretholdelse af antigen-bindende molekyler i blodplasma og fremgangsmåde til modifikation af immunogenicitet
KR20240027154A (ko) *	2011-03-30	2024-02-29	추가이 세이야쿠 가부시키가이샤	항원 결합 분자의 혈장 체류성과 면역원성을 개변하는 방법
MX340498B (es)	2011-06-30	2016-07-11	Chugai Pharmaceutical Co Ltd	Polipeptido heterodimerizado.
GB201112429D0 (en) *	2011-07-19	2011-08-31	Glaxo Group Ltd	Antigen-binding proteins with increased FcRn binding
KR20140076593A (ko)	2011-09-30	2014-06-20	추가이 세이야쿠 가부시키가이샤	항원의 소실을 촉진시키는 항원 결합 분자
WO2013047748A1 (ja)	2011-09-30	2013-04-04	中外製薬株式会社	複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201326209A (zh)	2011-09-30	2013-07-01	Chugai Pharmaceutical Co Ltd	具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
TWI681970B (zh)	2011-09-30	2020-01-11	日商中外製藥股份有限公司	包含依離子濃度之條件對抗原之結合活性會改變之抗原結合分域、及於pH中性之條件下對FcRn有結合活性之FcRn結合分域、且誘導對標的抗原的免疫反應之抗原結合分子
CA3186007A1 (en)	2011-09-30	2013-04-04	Chugai Seiyaku Kabushiki Kaisha	Ion concentration-dependent binding molecule library
US10851178B2 (en)	2011-10-10	2020-12-01	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
HK1198771A1 (en)	2011-11-30	2015-06-05	中外制药株式会社	Drug containing carrier into cell for forming immune complex
EP3539982B1 (en)	2011-12-23	2025-02-19	Pfizer Inc.	Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
KR102041412B1 (ko)	2011-12-30	2019-11-11	한미사이언스 주식회사	면역글로불린 Ｆｃ 단편 유도체
WO2013118858A1 (ja)	2012-02-09	2013-08-15	中外製薬株式会社	抗体のFc領域改変体
CN104125852B9 (zh)	2012-02-15	2017-05-17	弗·哈夫曼-拉罗切有限公司	基于Fc‑受体的亲和色谱
KR102219987B1 (ko)	2012-02-24	2021-02-25	추가이 세이야쿠 가부시키가이샤	ＦｃγＲＩＩＢ를 매개로 항원의 소실을 촉진하는 항원 결합 분자
MX382840B (es) *	2012-04-27	2025-03-13	Bioatla Llc	Regiones de anticuerpo modificado y sus usos.
AU2013268418B2 (en) *	2012-05-30	2017-12-07	Chugai Seiyaku Kabushiki Kaisha	Target-tissue-specific antigen-binding molecule
DK2857419T3 (da)	2012-05-30	2021-03-29	Chugai Pharmaceutical Co Ltd	Antigen-bindende molekyle til eliminering af aggregerede antigener
US11142563B2 (en)	2012-06-14	2021-10-12	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule containing modified Fc region
SG11201408538PA (en)	2012-07-13	2015-02-27	Roche Glycart Ag	Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
EP2889376A4 (en)	2012-08-24	2016-11-02	Chugai Pharmaceutical Co Ltd	ANTIBODIES Fc SPECIFIC TO FCTRII OF MOUSE
EP3721900A1 (en)	2012-08-24	2020-10-14	Chugai Seiyaku Kabushiki Kaisha	Fcgammariib-specific fc region variant
CN104870475B (zh)	2012-10-25	2019-11-08	美国比奥维拉迪维股份有限公司	抗补体C1s抗体和其用途
CN104884088B (zh)	2012-11-02	2018-06-15	美国比奥维拉迪维股份有限公司	抗补体C1s抗体和其用途
WO2014078866A2 (en) *	2012-11-19	2014-05-22	Xencor, Inc.	Engineered immunoglobulins with extended in vivo half-life
FR3003172B1 (fr) *	2013-03-15	2017-12-08	Lab Francais Du Fractionnement	Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
EP3557260B1 (en)	2012-12-21	2022-05-18	Chugai Seiyaku Kabushiki Kaisha	Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
TWI693073B (zh)	2012-12-21	2020-05-11	日商中外製藥股份有限公司	對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
WO2014104165A1 (ja)	2012-12-27	2014-07-03	中外製薬株式会社	ヘテロ二量化ポリペプチド
US10487155B2 (en)	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
US9701759B2 (en)	2013-01-14	2017-07-11	Xencor, Inc.	Heterodimeric proteins
US10131710B2 (en)	2013-01-14	2018-11-20	Xencor, Inc.	Optimized antibody variable regions
US9605084B2 (en)	2013-03-15	2017-03-28	Xencor, Inc.	Heterodimeric proteins
CA2898100C (en)	2013-01-14	2023-10-10	Xencor, Inc.	Novel heterodimeric proteins
US10968276B2 (en)	2013-03-12	2021-04-06	Xencor, Inc.	Optimized anti-CD3 variable regions
WO2014113510A1 (en)	2013-01-15	2014-07-24	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
TW201444867A (zh) *	2013-03-08	2014-12-01	Lilly Co Eli	抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
US10519242B2 (en)	2013-03-15	2019-12-31	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
US10106624B2 (en)	2013-03-15	2018-10-23	Xencor, Inc.	Heterodimeric proteins
DK2970486T3 (en)	2013-03-15	2018-08-06	Xencor Inc	MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
KR102318483B1 (ko)	2013-04-02	2021-10-27	추가이 세이야쿠 가부시키가이샤	Ｆｃ영역 개변체
CN104277112B (zh)	2013-07-04	2018-01-26	嘉和生物药业有限公司	长效降血糖融合蛋白
DK3050896T3 (da)	2013-09-27	2021-07-19	Chugai Pharmaceutical Co Ltd	Fremgangsmåde til fremstilling af en polypeptid-heteromultimer
KR102813659B1 (ko)	2013-11-11	2025-05-28	추가이 세이야쿠 가부시키가이샤	개변된 항체 가변영역을 포함하는 항원 결합 분자
EA201691154A1 (ru)	2013-12-04	2016-10-31	Чугаи Сейяку Кабусики Кайся	Антигенсвязывающие молекулы, активность связывания антигена которых варьируется в зависимости от концентрации соединений, и библиотеки указанных молекул
WO2015110930A1 (en)	2014-01-24	2015-07-30	Pfizer Inc.	Modified interleukin 21 receptor proteins
NZ711451A (en)	2014-03-07	2016-05-27	Alexion Pharma Inc	Anti-c5 antibodies having improved pharmacokinetics
PL3122781T3 (pl)	2014-03-28	2020-06-15	Xencor, Inc.	Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
US11760807B2 (en)	2014-05-08	2023-09-19	Chugai Seiyaku Kabushiki Kaisha	GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy
HRP20191766T1 (hr)	2014-11-06	2019-12-27	F. Hoffmann - La Roche Ag	Varijante fc regije s modificiranim vezanjem na neonatalni fc receptor (fcrn) i postupci primjene
MX386942B (es)	2014-11-21	2025-03-19	Bristol Myers Squibb Co	Anticuerpos que comprenden regiones constantes pesadas modificadas.
EA202090956A3 (ru)	2014-11-21	2020-12-30	Бристол-Майерс Сквибб Компани	Антитела к cd73 и их применения
PE20171103A1 (es)	2014-11-26	2017-08-07	Xencor Inc	Anticuerpos heterodimericos que se unen a cd3 y cd38
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
SMT202100521T1 (it)	2014-11-26	2021-11-12	Xencor Inc	Anticorpi eterodimerici che legano cd3 e cd20
MX2017005774A (es)	2014-12-19	2017-07-28	Chugai Pharmaceutical Co Ltd	Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EP3237449A2 (en)	2014-12-22	2017-11-01	Xencor, Inc.	Trispecific antibodies
MX389267B (es)	2014-12-23	2025-03-20	Bristol Myers Squibb Co	Anticuerpos contra el inmunorreceptor de células t con dominios de inmunoglobulina y de porción inhibidora con base en tirosina del inmumorreceptor (tigit).
CN107108729A (zh)	2015-02-05	2017-08-29	中外制药株式会社	包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
US10227411B2 (en)	2015-03-05	2019-03-12	Xencor, Inc.	Modulation of T cells with bispecific antibodies and FC fusions
CN108137687B (zh)	2015-05-29	2021-10-29	百时美施贵宝公司	抗ox40抗体及其用途
KR20180021833A (ko)	2015-06-29	2018-03-05	더 락커펠러 유니버시티	증진된 효능제 활성을 갖는 cd40에 대한 항체
KR102538745B1 (ko)	2015-09-18	2023-06-01	추가이 세이야쿠 가부시키가이샤	Il-8에 결합하는 항체 및 그의 사용
KR20180085800A (ko)	2015-12-07	2018-07-27	젠코어 인코포레이티드	Cd3 및 psma에 결합하는 이종이합체성 항체
CN108473562B (zh)	2015-12-18	2022-06-17	中外制药株式会社	抗-肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法
EP3394098A4 (en)	2015-12-25	2019-11-13	Chugai Seiyaku Kabushiki Kaisha	ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
KR20180118725A (ko)	2016-03-04	2018-10-31	브리스톨-마이어스 스큅 컴퍼니	항-cd73 항체와의 조합 요법
CN116063494A (zh)	2016-03-04	2023-05-05	洛克菲勒大学	具有增强的激动剂活性的cd40的抗体
AU2017285218B2 (en)	2016-06-14	2024-08-22	Xencor, Inc.	Bispecific checkpoint inhibitor antibodies
TWI760396B (zh)	2016-06-17	2022-04-11	日商中外製藥股份有限公司	抗肌抑素抗體及使用方法
CN109715663B (zh)	2016-06-28	2022-11-25	Xencor股份有限公司	结合生长抑素受体2的异源二聚抗体
CA3030099A1 (en)	2016-07-08	2018-01-11	Staten Biotechnology B.V.	Anti-apoc3 antibodies and methods of use thereof
CN118085091A (zh)	2016-08-02	2024-05-28	威特拉公司	工程化多肽及其应用
WO2018024162A1 (en) *	2016-08-03	2018-02-08	Sunshine Lake Pharma Co., Ltd.	Glp-1 fusion protein comprising mutated immunoglobulin fc portion
TWI831965B (zh)	2016-08-05	2024-02-11	日商中外製藥股份有限公司	Il-8相關疾病之治療用或預防用組成物
WO2018032638A1 (zh)	2016-08-19	2018-02-22	安源医药科技（上海）有限公司	用于构建融合蛋白的连接肽
CN106279437B (zh)	2016-08-19	2017-10-31	安源医药科技（上海）有限公司	高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759694B (zh)	2016-08-19	2023-01-13	安源医药科技（上海）有限公司	双特异性抗体及其制备方法与用途
US10793632B2 (en)	2016-08-30	2020-10-06	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
KR20240038176A (ko)	2016-10-14	2024-03-22	젠코어 인코포레이티드	IL15/IL15Rα 이종이량체 Fc-융합 단백질
US11286295B2 (en)	2016-10-20	2022-03-29	Sanofi	Anti-CHIKV monoclonal antibodies directed against the E2 structural protein
JP7181878B2 (ja) *	2017-01-13	2022-12-01	タイチョウハンチョンバイオファーマシューティクスインコーポレイテッド	Ｐｄ－１に対するモノクローナル抗体及びその適用
UY37651A (es)	2017-03-31	2018-10-31	Swedish Orphan Biovitrum Ab Publ	Polipéptido de unión al il-1r-i
TWI788340B (zh)	2017-04-07	2023-01-01	美商必治妥美雅史谷比公司	抗icos促效劑抗體及其用途
JP2020517242A (ja) *	2017-04-21	2020-06-18	スターテン・バイオテクノロジー・ベー・フェー	抗ＡｐｏＣ３抗体およびその使用方法
WO2018218056A1 (en)	2017-05-25	2018-11-29	Birstol-Myers Squibb Company	Antibodies comprising modified heavy constant regions
CA3067603A1 (en)	2017-06-30	2019-01-03	Xencor, Inc.	Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
CA3069756A1 (en)	2017-07-27	2019-01-31	Alexion Pharmaceuticals, Inc.	High concentration anti-c5 antibody formulations
CA3071234A1 (en)	2017-07-27	2019-01-31	Daiichi Sankyo Company, Limited	Anti-cd147 antibody
CN107857818A (zh) *	2017-08-07	2018-03-30	上海科新生物技术股份有限公司	一种针对IL‑17和TNF‑α的双特异性融合蛋白
ES2991804T3 (es) *	2017-09-19	2024-12-04	Tillotts Pharma Ag	Variantes de anticuerpos
BR112020008182A2 (pt)	2017-10-26	2020-10-27	Alexion Pharmaceuticals, Inc.	dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua)
SG11202003980PA (en)	2017-10-31	2020-05-28	Staten Biotechnology B V	Anti-apoc3 antibodies and methods of use thereof
US10538583B2 (en)	2017-10-31	2020-01-21	Staten Biotechnology B.V.	Anti-APOC3 antibodies and compositions thereof
JP2021502100A (ja)	2017-11-08	2021-01-28	ゼンコアインコーポレイテッド	新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
US10981992B2 (en)	2017-11-08	2021-04-20	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG11202005732XA (en)	2017-12-19	2020-07-29	Xencor Inc	Engineered il-2 fc fusion proteins
AU2018388791B2 (en) *	2017-12-19	2025-04-03	The Rockefeller University	Human IgG Fc domain variants with improved effector function
WO2019133747A1 (en)	2017-12-27	2019-07-04	Bristol-Myers Squibb Company	Anti-cd40 antibodies and uses thereof
CN112135632A (zh) *	2018-02-02	2020-12-25	肿瘤免疫股份有限公司	选择和设计用于癌症疗法的更安全且更有效的抗ctla-4抗体的方法
MX2020009296A (es)	2018-03-15	2020-11-13	Chugai Pharmaceutical Co Ltd	Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso.
CA3096052A1 (en)	2018-04-04	2019-10-10	Xencor, Inc.	Heterodimeric antibodies that bind fibroblast activation protein
US11505595B2 (en)	2018-04-18	2022-11-22	Xencor, Inc.	TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
CN112867734A (zh)	2018-04-18	2021-05-28	Xencor股份有限公司	包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
WO2019235426A1 (ja) *	2018-06-04	2019-12-12	中外製薬株式会社	細胞質内での半減期が変化した抗原結合分子
US12312394B2 (en)	2018-06-28	2025-05-27	Alexion Pharmaceuticals, Inc.	Methods of producing anti-C5 antibodies
CR20210127A (es)	2018-08-10	2021-04-19	Chugai Pharmaceutical Co Ltd	Molécula de unión al antigeno anti grupo de diferenciación 137 (cd137) y su uso
CN113105562B (zh)	2018-09-26	2023-12-01	安源医药科技（上海）有限公司	突变型单链人凝血因子viii在制备融合蛋白中的应用
JP7612571B2 (ja)	2018-10-03	2025-01-14	ゼンコアインコーポレイテッド	Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
JP2022512798A (ja) *	2018-10-25	2022-02-07	エフ．ホフマン－ラロシュアーゲー	抗体ＦｃＲｎ結合の改変
WO2020092549A1 (en)	2018-10-30	2020-05-07	Alexion Pharmaceuticals, Inc.	Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
BR112021008486A2 (pt)	2018-11-01	2021-10-26	Shandong New Time Pharmaceutical Co., Ltd	Anticorpo biespecífico e seu uso
JP2022513653A (ja)	2018-11-28	2022-02-09	ブリストル－マイヤーズスクイブカンパニー	修飾された重鎖定常領域を含む抗体
EP3892632A4 (en)	2018-12-05	2022-08-17	Bica Therapeutics Inc.	MODIFIED PRODUCT OF FC DOMAIN OF ANTIBODIES
JP2022522007A (ja) *	2019-02-27	2022-04-13	アンジーエックス・インコーポレーテッド	抗ｔｍ４ｓｆ１抗体を含む抗体薬物コンジュゲートおよびそれを使用する方法
BR112021016955A2 (pt)	2019-03-01	2021-11-23	Xencor Inc	Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
US20220153875A1 (en)	2019-03-19	2022-05-19	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
CN111722165B (zh)	2019-03-20	2023-02-28	Tdk株式会社	磁传感器、检测装置及检测系统
EP3954696A4 (en)	2019-04-10	2023-07-26	Chugai Seiyaku Kabushiki Kaisha	MODIFIED FC REGION ANTIBODY PURIFICATION METHOD
BR112022003529A2 (pt) *	2019-08-29	2022-05-24	Vir Biotechnology Inc	Composições e métodos para o tratamento da infecção por influenza a
JP7131527B2 (ja)	2019-10-24	2022-09-06	Tdk株式会社	磁気センサ及びその製造方法、並びに磁気検出装置及び磁気検出システム
WO2021122733A1 (en)	2019-12-18	2021-06-24	F. Hoffmann-La Roche Ag	Bispecific anti-ccl2 antibodies
PE20221585A1 (es)	2019-12-27	2022-10-06	Chugai Pharmaceutical Co Ltd	Anticuerpo anti antigeno-4 asociado al linfocito t citotoxico (ctla-4) y uso del mismo
JP7136137B2 (ja)	2020-01-29	2022-09-13	Tdk株式会社	磁気センサ、磁気検出装置及び磁気検出システム
TW202144395A (zh)	2020-02-12	2021-12-01	日商中外製藥股份有限公司	用於癌症之治療的抗cd137抗原結合分子
US11365239B2 (en)	2020-03-20	2022-06-21	Tsb Therapeutics (Beijing) Co., Ltd.	Anti-SARS-COV-2 antibodies and uses thereof
WO2021231976A1 (en)	2020-05-14	2021-11-18	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
WO2021231732A1 (en)	2020-05-15	2021-11-18	Bristol-Myers Squibb Company	Antibodies to garp
US20230183353A1 (en) *	2020-05-21	2023-06-15	Zydus Lifesciences Limited	Fc variant and preparation thereof
CN115803091A (zh)	2020-05-22	2023-03-14	福迈康股份公司	Ace2-fc融合蛋白及其用途
US11981718B2 (en)	2020-05-27	2024-05-14	Ampsource Biopharma Shanghai Inc.	Dual-function protein for lipid and blood glucose regulation
JPWO2021251438A1 (no)	2020-06-10	2021-12-16
KR20230035350A (ko)	2020-07-06	2023-03-13	플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨	SARS-CoV-2를 표적으로 하는 항원 결합 분자
KR102607909B1 (ko)	2020-08-19	2023-12-01	젠코어 인코포레이티드	항-cd28 조성물
AU2021332340A1 (en)	2020-08-26	2023-10-05	Flagship Pioneering Innovations Vi, Llc	Antigen binding molecules targeting sars-cov-2
JPWO2022044248A1 (no)	2020-08-28	2022-03-03
EP4211148A4 (en) *	2020-09-08	2024-11-06	Eutilex Co., Ltd.	Pd-1 polypeptide variants
TWI814094B (zh) *	2020-09-29	2023-09-01	美商碩騰服務公司	貓抗體變異體
JP2023547239A (ja)	2020-10-29	2023-11-09	フォーマイコンアーゲー	Ａｃｅ２融合タンパク質及びその使用方法
JP2024509543A (ja)	2021-03-03	2024-03-04	フォーマイコンアーゲー	ＡＣＥ２Ｆｃ融合タンパク質の製剤
WO2022192403A1 (en)	2021-03-09	2022-09-15	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and cldn6
US11859012B2 (en)	2021-03-10	2024-01-02	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and GPC3
WO2022263501A1 (en)	2021-06-18	2022-12-22	F. Hoffmann-La Roche Ag	Bispecific anti-ccl2 antibodies
IL309115A (en)	2021-06-25	2024-02-01	Chugai Pharmaceutical Co Ltd	Anti-CTLA-4 antibodies
TWI879694B (zh)	2021-06-25	2025-04-01	日商中外製藥股份有限公司	抗ctla-4抗體的用途
KR20240107200A (ko)	2021-09-02	2024-07-08	디제이에스 안티바디스 리미티드	폴리펩티드
WO2023056069A1 (en)	2021-09-30	2023-04-06	Angiex, Inc.	Degrader-antibody conjugates and methods of using same
US20250027067A1 (en)	2021-11-24	2025-01-23	Formycon Ag	Improved ace2 fusion proteins
WO2023094571A1 (en)	2021-11-25	2023-06-01	Formycon Ag	Stabilization of ace2 fusion proteins
KR20250054840A (ko)	2022-05-06	2025-04-23	제너레이트 바이오메디슨즈 인코포레이티드	Sars-cov-2를 표적으로 하는 항원 결합 분자
EP4536290A1 (en)	2022-06-08	2025-04-16	Angiex, Inc.	Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
US12110324B2 (en)	2022-07-22	2024-10-08	Flagship Pioneering Innovations Vi, Llc	Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2024107749A1 (en)	2022-11-16	2024-05-23	Attralus, Inc.	Fusion proteins that bind amyloid and the transferrin receptor and uses thereof
EP4386084A1 (en)	2022-12-14	2024-06-19	Formycon AG	Improved ace2 fusion proteins
US12319747B2 (en)	2023-07-03	2025-06-03	Medicovestor, Inc.	Methods of using anti-SP17 immunotherapeutics
TW202509078A (zh)	2023-07-07	2025-03-01	美商維里迪恩醫療股份有限公司	治療慢性甲狀腺眼病之方法
US20250099583A1 (en)	2023-09-06	2025-03-27	Viridian Therapeutics, Inc.	Pharmaceutical compositions of anti-igf-1r antibodies
WO2025101094A1 (en) *	2023-11-08	2025-05-15	Ооо «Geropharm»	Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates
WO2025108551A1 (en)	2023-11-23	2025-05-30	Mabylon Ag	Multispecific anti-allergen antibodies and uses thereof
WO2025109206A1 (en)	2023-11-22	2025-05-30	Mabylon Ag	Multispecific anti-allergen antibodies and uses thereof
WO2025136985A1 (en)	2023-12-17	2025-06-26	Viridian Therapeutics, Inc.	Compositions, doses, and methods for treatment of thyroid eye disease
GB202319605D0 (en) *	2023-12-20	2024-01-31	argenx BV	Monovalent binding molecules and methods of use
WO2025132503A1 (en)	2023-12-20	2025-06-26	F. Hoffmann-La Roche Ag	Antibodies binding to ceacam5

Family Cites Families (330)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US459007A (en)		1891-09-08		Porte
US1679307A (en)	1927-11-28	1928-07-31	William G Hutchison	Air circulator for stoves
US3135308A (en)	1960-07-14	1964-06-02	Allied Prod Corp	Threaded fastener and retained washer
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US3691016A (en)	1970-04-17	1972-09-12	Monsanto Co	Process for the preparation of insoluble enzymes
US3917002A (en)	1971-10-15	1975-11-04	Massey Ferguson Inc	Draft control linkage for a tractor
CU22545A1 (es)	1994-11-18	1999-03-31	Centro Inmunologia Molecular	Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
CA1023287A (en)	1972-12-08	1977-12-27	Boehringer Mannheim G.M.B.H.	Process for the preparation of carrier-bound proteins
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US3917008A (en)	1974-10-29	1975-11-04	Cities Service Co	Apparatus and process for preventing blow-outs
US4195128A (en)	1976-05-03	1980-03-25	Bayer Aktiengesellschaft	Polymeric carrier bound ligands
US4330440A (en)	1977-02-08	1982-05-18	Development Finance Corporation Of New Zealand	Activated matrix and method of activation
CA1093991A (en)	1977-02-17	1981-01-20	Hideo Hirohara	Enzyme immobilization with pullulan gel
US4229537A (en)	1978-02-09	1980-10-21	New York University	Preparation of trichloro-s-triazine activated supports for coupling ligands
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
WO1981001145A1 (en)	1979-10-18	1981-04-30	Univ Illinois	Hydrolytic enzyme-activatible pro-drugs
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4753894A (en)	1984-02-08	1988-06-28	Cetus Corporation	Monoclonal anti-human breast cancer antibodies
US4943533A (en)	1984-03-01	1990-07-24	The Regents Of The University Of California	Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
DE3675588D1 (de)	1985-06-19	1990-12-20	Ajinomoto Kk	Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4635308A (en)	1985-07-05	1987-01-13	Maggio Charles F	Method of using a bed sheet stay
WO1987005330A1 (en)	1986-03-07	1987-09-11	Michel Louis Eugene Bergh	Method for enhancing glycoprotein stability
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
CA1340935C (en)	1986-05-29	2000-03-28	Ian F.C. Mckenzie	Fc gamma receptor
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en)	1987-03-09	1987-04-15	Carlton Med Prod	Drug delivery systems
JP3101690B2 (ja)	1987-03-18	2000-10-23	エス・ビィ・２・インコーポレイテッド	変性抗体の、または変性抗体に関する改良
US4975278A (en)	1988-02-26	1990-12-04	Bristol-Myers Company	Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
NZ226414A (en)	1987-10-02	1992-07-28	Genentech Inc	Cd4 peptide adhesion variants and their preparation and use
JP3040121B2 (ja)	1988-01-12	2000-05-08	ジェネンテク，インコーポレイテッド	増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5576184A (en)	1988-09-06	1996-11-19	Xoma Corporation	Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5681566A (en)	1988-10-24	1997-10-28	3I Research Exploitation Limited	Antibody conjugates with two or more covalently linked FC regions
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US20040049014A1 (en)	1988-12-28	2004-03-11	Protein Design Labs, Inc.	Humanized immunoglobulins
US5266491A (en)	1989-03-14	1993-11-30	Mochida Pharmaceutical Co., Ltd.	DNA fragment and expression plasmid containing the DNA fragment
JP3051411B2 (ja)	1989-03-14	2000-06-12	持田製薬株式会社	新規ｄｎａならびにそれを含有する発現プラスミド
US5683888A (en)	1989-07-22	1997-11-04	University Of Wales College Of Medicine	Modified bioluminescent proteins and their use
US5017208A (en)	1989-09-11	1991-05-21	Gte Products Corporation	Apparatus for forming a groove in a glass tube
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1991006305A1 (en)	1989-11-07	1991-05-16	Bristol-Myers Squibb Company	Oligomeric immunoglobulins
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5292658A (en)	1989-12-29	1994-03-08	University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center	Cloning and expressions of Renilla luciferase
WO1991019515A1 (en)	1990-06-21	1991-12-26	The Board Of Trustees Of The Leland Stanford Junior University	Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity
US5198342A (en)	1990-07-05	1993-03-30	Immunex Corporation	DNA encoding IgA Fc receptors
KR930702029A (ko)	1990-08-31	1993-09-08	스티븐 체스노프	동종접합된 면역 글로불린
GB9022545D0 (en)	1990-10-17	1990-11-28	Wellcome Found	Culture medium
ES2204890T3 (es)	1991-03-06	2004-05-01	Merck Patent Gmbh	Anticuerpos monoclonales humanizados.
ES2142801T3 (es)	1991-03-11	2000-05-01	Univ Georgia Res Found	Clonacion y expresion de luciferasa de renilla.
GB9105245D0 (en)	1991-03-12	1991-04-24	Lynxvale Ltd	Binding molecules
US6797492B2 (en)	1991-05-17	2004-09-28	Merck & Co., Inc.	Method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
WO1992022324A1 (en)	1991-06-14	1992-12-23	Xoma Corporation	Microbially-produced antibody fragments and their conjugates
LU91067I2 (fr)	1991-06-14	2004-04-02	Genentech Inc	Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5264586A (en)	1991-07-17	1993-11-23	The Scripps Research Institute	Analogs of calicheamicin gamma1I, method of making and using the same
IE922437A1 (en)	1991-07-25	1993-01-27	Idec Pharma Corp	Recombinant antibodies for human therapy
US6329509B1 (en)	1991-08-14	2001-12-11	Genentech, Inc.	Anti-IgE antibodies
CA2116774C (en)	1991-09-19	2003-11-11	Paul J. Carter	Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
US5623053A (en)	1992-01-10	1997-04-22	California Institute Of Technology	Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
ZA932522B (en)	1992-04-10	1993-12-20	Res Dev Foundation	Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
WO1993022332A2 (en)	1992-04-24	1993-11-11	Board Of Regents, The University Of Texas System	Recombinant production of immunoglobulin-like domains in prokaryotic cells
DK0669836T3 (da)	1992-11-13	1996-10-14	Idec Pharma Corp	Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
US5736137A (en)	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
JP3720353B2 (ja)	1992-12-04	2005-11-24	メディカルリサーチカウンシル	多価および多重特異性の結合タンパク質、それらの製造および使用
US5885573A (en)	1993-06-01	1999-03-23	Arch Development Corporation	Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US20030108548A1 (en)	1993-06-01	2003-06-12	Bluestone Jeffrey A.	Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
EP0714409A1 (en)	1993-06-16	1996-06-05	Celltech Therapeutics Limited	Antibodies
GB9316989D0 (en)	1993-08-16	1993-09-29	Lynxvale Ltd	Binding molecules
KR960705209A (ko)	1993-09-10	1996-10-09	잭 엠. 그랜노위츠	녹색 형광 단백의 용도
GB9401182D0 (en)	1994-01-21	1994-03-16	Inst Of Cancer The Research	Antibodies to EGF receptor and their antitumour effect
WO1995021191A1 (en)	1994-02-04	1995-08-10	William Ward	Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
WO1995026403A1 (en)	1994-03-29	1995-10-05	Celltech Therapeutics Limited	Antibodies against e-selectin
US5773001A (en)	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5541087A (en)	1994-09-14	1996-07-30	Fuji Immunopharmaceuticals Corporation	Expression and export technology of proteins as immunofusins
US5804396A (en)	1994-10-12	1998-09-08	Sugen, Inc.	Assay for agents active in proliferative disorders
US6214388B1 (en)	1994-11-09	2001-04-10	The Regents Of The University Of California	Immunoliposomes that optimize internalization into target cells
US5777079A (en)	1994-11-10	1998-07-07	The Regents Of The University Of California	Modified green fluorescent proteins
ATE331438T1 (de)	1995-01-17	2006-07-15	Brigham & Womens Hospital	Rezeptorspezifischer transepithelealer transport von immunogenen
US6030613A (en)	1995-01-17	2000-02-29	The Brigham And Women's Hospital, Inc.	Receptor specific transepithelial transport of therapeutics
US6485726B1 (en)	1995-01-17	2002-11-26	The Brigham And Women's Hospital, Inc.	Receptor specific transepithelial transport of therapeutics
US6086875A (en)	1995-01-17	2000-07-11	The Brigham And Women's Hospital, Inc.	Receptor specific transepithelial transport of immunogens
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
EP2163546B1 (en)	1995-03-30	2016-06-01	Pfizer Products Inc.	Quinazoline derivatives
US6096871A (en) *	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6121022A (en)	1995-04-14	2000-09-19	Genentech, Inc.	Altered polypeptides with increased half-life
GB9508565D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quiazoline derivative
US6444789B1 (en)	1995-05-03	2002-09-03	Applied Research Systems Ars Holding N.V.	CD16-II variants
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en)	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
JPH11507535A (ja)	1995-06-07	1999-07-06	イムクローンシステムズインコーポレイテッド	腫瘍の成長を抑制する抗体および抗体フラグメント類
US6365161B1 (en)	1995-06-07	2002-04-02	Medarex, Inc.	Therapeutic compounds comprised of anti-FC receptor binding agents
US5790396A (en)	1995-12-19	1998-08-04	Kabushiki Kaisha Toshiba	Neutral point clamped (NPC) inverter control system
US5874304A (en)	1996-01-18	1999-02-23	University Of Florida Research Foundation, Inc.	Humanized green fluorescent protein genes and methods
US5804387A (en)	1996-02-01	1998-09-08	The Board Of Trustees Of The Leland Stanford Junior University	FACS-optimized mutants of the green fluorescent protein (GFP)
US6750334B1 (en)	1996-02-02	2004-06-15	Repligen Corporation	CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US5876995A (en)	1996-02-06	1999-03-02	Bryan; Bruce	Bioluminescent novelty items
WO1997034631A1 (en)	1996-03-18	1997-09-25	Board Of Regents, The University Of Texas System	Immunoglobin-like domains with increased half lives
ATE267610T1 (de)	1996-03-20	2004-06-15	Immunomedics Inc	Glykosylierte igg antikörper
EE05289B1 (et)	1996-04-12	2010-04-15	Warner-Lambert Company	Türosiinkinaaside pöördumatud inhibiitorid, farmatseutiline kompositsioon, kasutamine
WO1997043316A1 (en)	1996-05-10	1997-11-20	Beth Israel Deaconess Medical Center, Inc.	Physiologically active molecules with extended half-lives and methods of using same
US5834597A (en)	1996-05-20	1998-11-10	Protein Design Labs, Inc.	Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5925558A (en)	1996-07-16	1999-07-20	The Regents Of The University Of California	Assays for protein kinases using fluorescent protein substrates
JP2000516452A (ja)	1996-07-16	2000-12-12	プリュックテュン，アンドレアス	可溶性が増大した免疫グロブリンスーパーファミリードメインおよびフラグメント
CA2262405A1 (en)	1996-08-02	1998-02-12	Bristol-Myers Squibb Company	A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
US6063756A (en)	1996-09-24	2000-05-16	Monsanto Company	Bacillus thuringiensis cryET33 and cryET34 compositions and uses therefor
US5976796A (en)	1996-10-04	1999-11-02	Loma Linda University	Construction and expression of renilla luciferase and green fluorescent protein fusion genes
WO1998023289A1 (en) *	1996-11-27	1998-06-04	The General Hospital Corporation	MODULATION OF IgG BINDING TO FcRn
ATE290205T1 (de)	1996-12-12	2005-03-15	Prolume Ltd	Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen
WO1998031806A2 (en)	1997-01-21	1998-07-23	Human Genome Sciences, Inc.	Fc RECEPTORS AND POLYPEPTIDES
US6277375B1 (en)	1997-03-03	2001-08-21	Board Of Regents, The University Of Texas System	Immunoglobulin-like domains with increased half-lives
UA73073C2 (uk)	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
EP1255209A3 (en)	1997-04-11	2009-02-11	California Institute Of Technology	Apparatus and method for automated protein design
WO1998047089A1 (en)	1997-04-11	1998-10-22	California Institute Of Technology	Apparatus and method for automated protein design
EP0915987A2 (en)	1997-04-21	1999-05-19	Donlar Corporation	POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
US20020062010A1 (en)	1997-05-02	2002-05-23	Genentech, Inc.	Method for making multispecific antibodies having heteromultimeric and common components
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
EP0983303B1 (en)	1997-05-21	2006-03-08	Biovation Limited	Method for the production of non-immunogenic proteins
GB9712892D0 (en)	1997-06-20	1997-08-20	Eclagen Ltd	Identification of mhc binding peptides
US20040191256A1 (en)	1997-06-24	2004-09-30	Genentech, Inc.	Methods and compositions for galactosylated glycoproteins
ZA986729B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitors of tyrosine kinases
ZA986732B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
TW436485B (en)	1997-08-01	2001-05-28	American Cyanamid Co	Substituted quinazoline derivatives
US6340824B1 (en)	1997-09-01	2002-01-22	Kabushiki Kaisha Toshiba	Semiconductor light emitting device including a fluorescent material
US20030105294A1 (en)	1998-02-25	2003-06-05	Stephen Gillies	Enhancing the circulating half life of antibody-based fusion proteins
ATE388224T1 (de)	1998-03-27	2008-03-15	Prolume Ltd	Luciferase, gfp fluoreszenzproteine, kodierende nukleinsaüre und ihre verwendung in der diagnose
DE69937291T2 (de)	1998-04-02	2008-07-10	Genentech, Inc., South San Francisco	Antikörpervarianten und fragmente davon
US6242195B1 (en)	1998-04-02	2001-06-05	Genentech, Inc.	Methods for determining binding of an analyte to a receptor
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
US6528624B1 (en)	1998-04-02	2003-03-04	Genentech, Inc.	Polypeptide variants
AU3655899A (en)	1998-04-20	1999-11-08	Regents Of The University Of California, The	Modified immunoglobulin molecules and methods for use thereof
DK1071700T3 (da)	1998-04-20	2010-06-07	Glycart Biotechnology Ag	Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
EP1082137A4 (en)	1998-05-06	2004-05-19	Univ Temple	REVERSE OF PERCENTAL RESPONSE BY INTERRUPTING THE MACROPHAGE RECEPTOR FcSg (g) RI
GB9809951D0 (en)	1998-05-08	1998-07-08	Univ Cambridge Tech	Binding molecules
GB9815157D0 (en)	1998-07-13	1998-09-09	Metron Designs Ltd	High resolution pulse width setting from relatively low frequency clocks
JP2002522063A (ja)	1998-08-17	2002-07-23	アブジェニックスインコーポレイテッド	増加した血清半減期を有する改変された分子の生成
US6306926B1 (en)	1998-10-07	2001-10-23	3M Innovative Properties Company	Radiopaque cationically polymerizable compositions comprising a radiopacifying filler, and method for polymerizing same
US6403312B1 (en)	1998-10-16	2002-06-11	Xencor	Protein design automatic for protein libraries
JP2003527072A (ja)	1998-10-16	2003-09-16	ゼンコー	蛋白質ライブラリーに関する蛋白質設計オートメーション
US20030049654A1 (en)	1998-10-16	2003-03-13	Xencor	Protein design automation for protein libraries
US20020048772A1 (en)	2000-02-10	2002-04-25	Dahiyat Bassil I.	Protein design automation for protein libraries
US7315786B2 (en)	1998-10-16	2008-01-01	Xencor	Protein design automation for protein libraries
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
WO2000034317A2 (en)	1998-12-08	2000-06-15	Biovation Limited	Method for reducing immunogenicity of proteins
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
KR101155191B1 (ko) *	1999-01-15	2012-06-13	제넨테크, 인크.	효과기 기능이 변화된 폴리펩티드 변이체
US6221556B1 (en)	1999-03-05	2001-04-24	General Electric Company	Article for optical data storage device
EP2270147B2 (en)	1999-04-09	2020-07-22	Kyowa Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
US6663862B1 (en)	1999-06-04	2003-12-16	Duke University	Reagents for detection and purification of antibody fragments
AU781478B2 (en)	1999-08-20	2005-05-26	Johns Hopkins University School Of Medicine, The	Methods and compositions for the construction and use of fusion libraries
US6649165B2 (en)	1999-09-07	2003-11-18	Walter Schubert	Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using soluble FcγRIII receptors
GB9922283D0 (en)	1999-09-22	1999-11-17	Kennedy Rheumatology Inst	Adenoviral vectors
JP4668498B2 (ja)	1999-10-19	2011-04-13	協和発酵キリン株式会社	ポリペプチドの製造方法
ES2568625T3 (es)	1999-11-29	2016-05-03	The Trustees Of Columbia University In The City Of New York	Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma
AU2001241410A1 (en)	2000-01-31	2001-08-07	Human Genome Sciences, Inc.	Nucleic acids, proteins, and antibodies
AU781544B2 (en)	2000-02-03	2005-05-26	Lennart Hammarstrom	Ruminant MHC class I-like Fc receptors
EP1255826B1 (en)	2000-02-10	2005-09-14	Xencor	Protein design automation for protein libraries
NZ520789A (en)	2000-02-11	2005-01-28	Biogen Inc	Heterologous polypeptide of the TNF family
ATE419354T1 (de)	2000-02-25	2009-01-15	Us Gov Health & Human Serv	Scfv-moleküle gegen egfrviii mit verbesserter zytotoxizität und ausbeute, darauf basierte immuntoxine, und verfahren zur deren verwendung
US7687461B2 (en)	2000-03-02	2010-03-30	Xencor, Inc.	Treatment of TNF-α related disorders with TNF-α variant proteins
US7244823B2 (en)	2000-03-02	2007-07-17	Xencor	TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7056695B2 (en)	2000-03-02	2006-06-06	Xencor	TNF-α variants
US7101974B2 (en)	2000-03-02	2006-09-05	Xencor	TNF-αvariants
US7449443B2 (en)	2000-03-23	2008-11-11	California Institute Of Technology	Method for stabilization of proteins using non-natural amino acids
CN101289511A (zh) *	2000-04-11	2008-10-22	杰南技术公司	多价抗体及其应用
US7416726B2 (en)	2000-04-13	2008-08-26	The Rockefeller University	Enhancement of antibody-mediated immune responses
WO2001088138A1 (en)	2000-05-19	2001-11-22	Scancell Limited	Humanised antibodies to the epidermal growth factor receptor
US6358733B1 (en)	2000-05-19	2002-03-19	Apolife, Inc.	Expression of heterologous multi-domain proteins in yeast
US6586207B2 (en)	2000-05-26	2003-07-01	California Institute Of Technology	Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
AP2002002454A0 (en)	2000-06-28	2002-06-30	Bakulesh Mafatlal Khamar	Agents for reversal of drug resistance in mycobacterium tuberculosis.
US20020119492A1 (en)	2000-07-10	2002-08-29	Chirino Arthur J.	Protein design automation for designing protein libraries with altered immunogenicity
US20030068649A1 (en)	2000-09-14	2003-04-10	Doberstein Stephen K.	Methods and compositions for the construction and use of fusion libraries
WO2002022826A2 (en)	2000-09-14	2002-03-21	Xencor, Inc.	Methods and compositions for the construction and use of fusion libraries
US20030036643A1 (en)	2000-09-14	2003-02-20	Jin Cheng He	Methods and compositions for the construction and use of fusion libraries
BR0114475A (pt)	2000-10-06	2003-12-23	Kyowa Hakko Kogyo Kk	Célula para a produção de composição de anticorpo
WO2002030954A1 (fr)	2000-10-06	2002-04-18	Kyowa Hakko Kogyo Co., Ltd.	Procede de purification d'un anticorps
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
US7465790B2 (en)	2000-10-09	2008-12-16	Isis Innovation, Inc.	Therapeutic antibodies
US6992234B2 (en)	2000-11-06	2006-01-31	The Jackson Laboratory	FcRn-based therapeutics for the treatment of auto-immune disorders
US7235643B2 (en)	2000-11-07	2007-06-26	Morphotek, Inc.	Antibodies and methods for generating genetically altered antibodies with high affinity
GB0029407D0 (en)	2000-12-01	2001-01-17	Affitech As	Product
US20040253242A1 (en)	2000-12-05	2004-12-16	Bowdish Katherine S.	Rationally designed antibodies
EP2357187A1 (en)	2000-12-12	2011-08-17	MedImmune, LLC	Molecules with extended half-lives, compositions and uses thereof
US20030124537A1 (en)	2000-12-14	2003-07-03	Yuan-Chin Liu	Procaryotic libraries and uses
ATE405650T1 (de)	2000-12-14	2008-09-15	Genentech Inc	Produktion von ganzen antikörpern in prokaryontischen zellen
US6979556B2 (en)	2000-12-14	2005-12-27	Genentech, Inc.	Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
EP1244152A3 (en)	2001-01-26	2008-12-03	Toyoda Gosei Co., Ltd.	Reflective light emitting diode, reflective optical device and its manufacturing method
EP1358337A1 (en)	2001-01-30	2003-11-05	Degussa AG	Nucleotide sequences which code for the otsa gene of c. glutamicum
AU2002256624B2 (en)	2001-02-19	2007-12-06	Merck Patent Gmbh	Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
HUP0303171A2 (hu)	2001-02-19	2003-12-29	Merck Patent Gmbh	Csökkentett immunogenitású mesterséges fehérjék
US20020168640A1 (en)	2001-02-22	2002-11-14	Min Li	Biochips comprising nucleic acid/protein conjugates
WO2002068698A2 (en)	2001-02-22	2002-09-06	Xencor, Inc.	Use of nucleic acid libraries to create toxicological profiles
AU2002251999A1 (en)	2001-02-22	2002-09-12	Xencor	Methods and compositions for the construction and use of fusion libraries using computational protein design methods
AU2002254374A1 (en)	2001-03-23	2002-10-08	Genencor International, Inc.	Proteins producing an altered immunogenic response and methods of making and using the same
US6992174B2 (en)	2001-03-30	2006-01-31	Emd Lexigen Research Center Corp.	Reducing the immunogenicity of fusion proteins
CA2442801A1 (en)	2001-04-02	2002-10-10	Idec Pharmaceutical Corporation	Recombinant antibodies coexpressed with gntiii
US7117096B2 (en)	2001-04-17	2006-10-03	Abmaxis, Inc.	Structure-based selection and affinity maturation of antibody library
MXPA03011094A (es)	2001-05-31	2004-12-06	Medarex Inc	Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello.
CA2385745C (en)	2001-06-08	2015-02-17	Abbott Laboratories (Bermuda) Ltd.	Methods of administering anti-tnf.alpha. antibodies
BRPI0210405B8 (pt)	2001-06-13	2021-05-25	Genmab As	anticorpo monoclonal humano, molécula biespecífica, método in vitro para inibir o crescimento de uma célula expressando egfr, para induzir a citólise de uma célula expressando egfr, e para detectar a presença de antígeno egfr ou uma célula expressando egfr em uma amostra, e, vetor de expressão
CA2452824A1 (en)	2001-07-10	2003-01-23	Xencor	Protein design automation for designing protein libraries with altered immunogenicity
US20030022285A1 (en)	2001-07-10	2003-01-30	Chirino Arthur J.	Protein design automation for designing protein libraries with altered immunogenicity
GB0118662D0 (en)	2001-07-31	2001-09-19	Univ Southampton	Binding agents
KR20040054669A (ko)	2001-08-03	2004-06-25	글리카트 바이오테크놀로지 아게	항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체
US7497862B2 (en)	2001-08-03	2009-03-03	Tyco Healthcare Group Lp	Tissue marking apparatus and method
US20030130827A1 (en)	2001-08-10	2003-07-10	Joerg Bentzien	Protein design automation for protein libraries
US7255858B2 (en)	2001-08-10	2007-08-14	University Of Virginia Patent Foundation	Enhancing the efficacy of immunotherapies by supplementing with complement
PL213948B1 (pl)	2001-10-25	2013-05-31	Genentech Inc	Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US6911321B2 (en)	2001-12-19	2005-06-28	Genentech, Inc.	Non-human primate Fc receptors and methods of use
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
IL162835A0 (en)	2002-01-09	2005-11-20	Medarex Inc	Human monoclonal antibodies against cd30
JP2006506943A (ja)	2002-02-11	2006-03-02	ジェネンテック・インコーポレーテッド	抗原結合速度の大きい抗体変異体
US20040002587A1 (en)	2002-02-20	2004-01-01	Watkins Jeffry D.	Fc region variants
US7139665B2 (en)	2002-02-27	2006-11-21	California Institute Of Technology	Computational method for designing enzymes for incorporation of non natural amino acids into proteins
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US20070122406A1 (en)	2005-07-08	2007-05-31	Xencor, Inc.	Optimized proteins that target Ep-CAM
WO2003074679A2 (en)	2002-03-01	2003-09-12	Xencor	Antibody optimization
US8093357B2 (en)	2002-03-01	2012-01-10	Xencor, Inc.	Optimized Fc variants and methods for their generation
CA2480404A1 (en)	2002-03-25	2003-10-30	Uab Research Foundation	Fc receptor homolog, reagents, and uses thereof
WO2003085119A1 (fr)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia
WO2005056606A2 (en)	2003-12-03	2005-06-23	Xencor, Inc	Optimized antibodies that target the epidermal growth factor receptor
EP1539246A4 (en)	2002-07-03	2007-05-16	Brigham & Womens Hospital	ADMINISTRATION IN THE CENTRAL AIRWAYS FOR THE SYSTEMIC DELIVERY OF THERAPEUTICS
JP2006500009A (ja)	2002-07-09	2006-01-05	ジェネンテック・インコーポレーテッド	腫瘍の診断と治療のための組成物と方法
WO2004016750A2 (en)	2002-08-14	2004-02-26	Macrogenics, Inc.	FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
US20040033228A1 (en)	2002-08-16	2004-02-19	Hans-Juergen Krause	Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004022717A2 (en)	2002-09-05	2004-03-18	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen
US20050271660A1 (en) *	2002-09-06	2005-12-08	Alexion Pharmaceuticals, Inc.	Nebulization of monoclonal antibodies for treating pulmonary diseases
JP2005539067A (ja)	2002-09-16	2005-12-22	エリューシスセラピューティクス，インコーポレーテッド	ポリエチレングリコールリンカーを用いる二重特異性分子の産生
US20060235208A1 (en)	2002-09-27	2006-10-19	Xencor, Inc.	Fc variants with optimized properties
EP3321282A1 (en)	2002-09-27	2018-05-16	Xencor, Inc.	Optimized fc variants and methods for their generation
US7365168B2 (en)	2002-10-15	2008-04-29	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP4768439B2 (ja) *	2002-10-15	2011-09-07	アボットバイオセラピューティクスコーポレイション	変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
US7361740B2 (en) *	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en)	2002-10-15	2007-05-15	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ATE470675T1 (de)	2002-12-16	2010-06-15	Genentech Inc	Immunoglobulinvarianten und deren verwendungen
CA2512693A1 (en)	2003-01-08	2004-07-29	Xencor, Inc.	Novel proteins with altered immunogenicity
US7960512B2 (en)	2003-01-09	2011-06-14	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2512729C (en)	2003-01-09	2014-09-16	Macrogenics, Inc.	Identification and engineering of antibodies with variant fc regions and methods of using same
US8388955B2 (en)	2003-03-03	2013-03-05	Xencor, Inc.	Fc variants
US7610156B2 (en)	2003-03-31	2009-10-27	Xencor, Inc.	Methods for rational pegylation of proteins
JP4869064B2 (ja)	2003-04-04	2012-02-01	ジェネンテック，インコーポレイテッド	高濃度抗体及びタンパク質製剤
EP1613649A2 (en)	2003-04-04	2006-01-11	Ingenium Pharmaceuticals AG	Spinster-like protein genes, expression products, non-human animal model: uses in human metabolic disorders
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
AR044388A1 (es)	2003-05-20	2005-09-07	Applied Molecular Evolution	Moleculas de union a cd20
JP2007501021A (ja)	2003-05-30	2007-01-25	アレクシオンファーマシューティカルズ，インコーポレイテッド	遺伝子操作された定常領域を含む、抗体および融合タンパク質
PT1641483E (pt)	2003-06-12	2008-04-29	Lilly Co Eli	Proteínas de fusão
US20040254108A1 (en)	2003-06-13	2004-12-16	Jing Ma	Preparation and application of anti-tumor bifunctional fusion proteins
WO2005000898A2 (en)	2003-06-27	2005-01-06	Biogen Idec Ma Inc.	Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
EP1644416A4 (en)	2003-06-30	2007-08-29	Centocor Inc	ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
DK1648507T3 (en)	2003-07-24	2017-05-01	Innate Pharma Sa	PROCEDURES AND COMPOSITIONS FOR INCREASING THE EFFECTIVENESS OF THERAPEUTIC ANTIBODIES USING COMPOUNDS THAT POTENTATE NK CELLS
CA2533593A1 (en)	2003-07-26	2005-02-10	Biogen Idec Ma Inc.	Altered antibodies having improved antigen-binding affinity
EP1660970A4 (en)	2003-08-01	2007-02-14	Dna Twopointo Inc	SYSTEMS AND METHODS FOR BIOPOLYMER TECHNOLOGY
EP2502935B1 (en)	2003-08-22	2017-03-29	Biogen MA Inc.	Improved antibodies having altered effector function and methods for making the same
US20050152894A1 (en)	2003-09-05	2005-07-14	Genentech, Inc.	Antibodies with altered effector functions
CA2579635A1 (en)	2003-09-10	2005-03-17	Baxter International Inc.	Peptides that inhibit complement activation
EP1675620B1 (en)	2003-10-09	2019-05-08	Ambrx, Inc.	Polymer derivatives
CA2545539A1 (en)	2003-10-15	2005-04-28	Pdl Biopharma, Inc.	Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
GB0324368D0 (en)	2003-10-17	2003-11-19	Univ Cambridge Tech	Polypeptides including modified constant regions
WO2005063815A2 (en)	2003-11-12	2005-07-14	Biogen Idec Ma Inc.	Fcϝ receptor-binding polypeptide variants and methods related thereto
EP1697415A1 (en)	2003-11-12	2006-09-06	Biogen Idec MA Inc.	NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
JP2007512846A (ja)	2003-12-04	2007-05-24	ゼンコー・インコーポレイテッド	増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
UA86605C2 (ru)	2004-01-12	2009-05-12	Аплайд Молекьюлер Иволюшн, Инк.	Антитело, которое содержит вариант исходного человеческого fс-участка
MXPA06008496A (es)	2004-02-02	2007-01-30	Ambrx Inc	Polipeptidos de interferon humano modificados y sus usos.
AU2005227326B2 (en)	2004-03-24	2009-12-03	Xencor, Inc.	Immunoglobulin variants outside the Fc region
TWI439284B (zh)	2004-04-09	2014-06-01	Abbvie Biotechnology Ltd	用於治療ＴＮＦα相關失調症之多重可變劑量療法
WO2005123780A2 (en)	2004-04-09	2005-12-29	Protein Design Labs, Inc.	Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
EP1747237A4 (en)	2004-04-16	2008-05-21	Macrogenics Inc	SPECIFIC GAMMA FC ANTIBODIES AND METHODS OF USING THE SAME
US7521542B2 (en)	2004-05-10	2009-04-21	Macrogenics, Inc.	Humanized FcγRIIB-specific antibodies and methods of use thereof
KR100545720B1 (ko)	2004-05-31	2006-01-24	메덱스젠 주식회사	당화된 면역글로불린 및 이를 포함하는 면역접합체
WO2006085967A2 (en)	2004-07-09	2006-08-17	Xencor, Inc.	OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
SI2471813T1 (sl)	2004-07-15	2015-03-31	Xencor, Inc.	Optimirane Fc variante
CN101721701A (zh)	2004-07-23	2010-06-09	健泰科生物技术公司	抗体或其片段的结晶
BR122018016031B8 (pt)	2004-08-04	2021-07-27	Applied Molecular Evolution Inc	processo para produzir um anticorpo monoclonal variante com resposta de adcc realçada
RU2367667C2 (ru) *	2004-08-19	2009-09-20	Дженентек, Инк.	Полипептидные варианты с измененной эффекторной функцией
HUE030079T2 (en)	2004-09-23	2017-04-28	Genentech Inc	Cysteine-manipulated antibodies and conjugates
WO2006043972A1 (en)	2004-10-12	2006-04-27	Amprotein Corporation	Chimeric protein
CA2587766A1 (en)	2004-11-10	2007-03-01	Macrogenics, Inc.	Engineering fc antibody regions to confer effector function
US8802820B2 (en)	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
US8367805B2 (en) *	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
CN102746404B (zh) *	2004-11-12	2016-01-20	赞科股份有限公司	对FcRn的结合被改变的Fc变体
US8546543B2 (en) *	2004-11-12	2013-10-01	Xencor, Inc.	Fc variants that extend antibody half-life
US20070135620A1 (en) *	2004-11-12	2007-06-14	Xencor, Inc.	Fc variants with altered binding to FcRn
WO2006076594A2 (en)	2005-01-12	2006-07-20	Xencor, Inc.	Antibodies and fc fusion proteins with altered immunogenicity
WO2006105062A2 (en)	2005-03-29	2006-10-05	Verenium Corporation	Altered antibody fc regions and uses thereof
CA2602663A1 (en)	2005-03-31	2006-10-05	Xencor, Inc.	Fc variants with optimized properties
US8163881B2 (en)	2005-05-31	2012-04-24	The Board Of Regents Of The University Of Texas System	Immunoglobulin molecules with improved characteristics
SI1919503T1 (sl)	2005-08-10	2015-02-27	Macrogenics, Inc.	Identifikacija in inĺ˝eniring protiteles z variantnimi fc regijami in postopki za njih uporabo
WO2007041635A2 (en)	2005-10-03	2007-04-12	Xencor, Inc.	Fc variants with optimized fc receptor binding properties
JP4860703B2 (ja)	2005-10-06	2012-01-25	ゼンコー・インコーポレイテッド	最適化された抗ｃｄ３０抗体
US20070087005A1 (en)	2005-10-14	2007-04-19	Lazar Gregory A	Anti-glypican-3 antibody
EP1943332A4 (en) *	2005-10-14	2011-04-13	Medimmune Inc	CELLULAR DISPLAY OF ANTIBODY LIBRARIES
EP1988922A4 (en)	2006-02-03	2010-06-02	Medimmune Llc	PROTEIN FORMULATIONS
BR122017024057B8 (pt) *	2006-03-15	2021-05-25	Alexion Pharma Inc	anticorpo que se liga à c5 e composição farmacêutica compreendendo dito anticorpo e um veículo farmaceuticamente aceitável
PL2029173T3 (pl)	2006-06-26	2017-04-28	Macrogenics, Inc.	Przeciwciała swoiste dla FC RIIB i sposoby ich zastosowania
US20100166741A1 (en)	2006-07-13	2010-07-01	Genentech , Inc.	Altered br-3 binding polypeptides
US8911964B2 (en)	2006-09-13	2014-12-16	Abbvie Inc.	Fed-batch method of making human anti-TNF-alpha antibody
CA2842966A1 (en)	2006-09-13	2008-03-20	Abbvie Inc.	Cell culture improvements
US20080112961A1 (en)	2006-10-09	2008-05-15	Macrogenics, Inc.	Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
CA2667655A1 (en)	2006-10-27	2008-05-15	Abbott Biotechnology Ltd.	Crystalline anti-htnfalpha antibodies
WO2008070780A1 (en)	2006-12-07	2008-06-12	Novartis Ag	Antagonist antibodies against ephb3
US8652466B2 (en)	2006-12-08	2014-02-18	Macrogenics, Inc.	Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
US20090068110A1 (en)	2006-12-22	2009-03-12	Genentech, Inc.	Antibodies to insulin-like growth factor receptor
JP4226632B2 (ja)	2007-03-08	2009-02-18	ファナック株式会社	異常時モータ減速停止制御手段を有する数値制御装置
WO2008134046A1 (en)	2007-04-27	2008-11-06	Genentech, Inc.	Potent, stable and non-immunosuppressive anti-cd4 antibodies
JP2010531890A (ja)	2007-06-26	2010-09-30	メディミューン，エルエルシー	Ｒｓｖ感染症及び関連する症状の治療方法
US8883146B2 (en)	2007-11-30	2014-11-11	Abbvie Inc.	Protein formulations and methods of making same
ES2742268T3 (es)	2007-12-26	2020-02-13	Xencor Inc	Variantes de Fc con unión alterada a FcRn
BRPI0910482A2 (pt)	2008-04-29	2019-09-24	Abbott Lab	imunoglobinas de domínio variável duplo e usos das mesmas
NZ592095A (en)	2008-10-20	2013-01-25	Abbott Lab	Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
US10817851B2 (en)	2009-12-23	2020-10-27	Aristocrat Technologies Australia Pty Limited	System and method for cashless gaming
CN105854016A (zh)	2010-11-11	2016-08-17	艾伯维生物技术有限公司	改进的高浓度抗TNFα抗体液体制剂
US9917808B2 (en)	2013-03-14	2018-03-13	International Business Machines Corporation	Grouping electronic messages
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
US20140294812A1 (en)	2013-03-15	2014-10-02	Xencor, Inc.	Fc variants that improve fcrn binding and/or increase antibody half-life
CA2935055C (en)	2014-01-10	2021-08-24	Santen Pharmaceutical Co., Ltd.	Pharmaceutical composition containing pyridylaminoacetic acid compound
EP3119890A4 (en)	2014-03-19	2017-12-27	Duke University	Swarm immunization with envelopes from ch505
JP5939345B1 (ja)	2015-11-06	2016-06-22	株式会社オートネットワーク技術研究所	端子金具およびコネクタ
JP6824666B2 (ja)	2016-08-31	2021-02-03	株式会社ジャパンディスプレイ	表示装置
US11392902B2 (en)	2017-06-06	2022-07-19	United Parcel Service Of America, Inc.	Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery
US10650956B2 (en)	2017-06-16	2020-05-12	Fanuc Corporation	Reactor having iron cores and coils

2008
- 2008-12-22 ES ES14171372T patent/ES2742268T3/es active Active
- 2008-12-22 SI SI200832083T patent/SI2808343T1/sl unknown
- 2008-12-22 EP EP08866130.1A patent/EP2235059B1/en active Active
- 2008-12-22 DK DK08866130T patent/DK2235059T3/en active
- 2008-12-22 EP EP14171372.7A patent/EP2808343B8/en active Active
- 2008-12-22 AU AU2008345242A patent/AU2008345242B2/en active Active
- 2008-12-22 PL PL14171372T patent/PL2808343T3/pl unknown
- 2008-12-22 CA CA3086659A patent/CA3086659A1/en not_active Abandoned
- 2008-12-22 RU RU2010130851/10A patent/RU2529951C2/ru active
- 2008-12-22 JP JP2010540845A patent/JP5726534B2/ja active Active
- 2008-12-22 DK DK14171372.7T patent/DK2808343T3/da active
- 2008-12-22 LT LTEP14171372.7T patent/LT2808343T/lt unknown
- 2008-12-22 BR BR122021010656-8A patent/BR122021010656B1/pt active IP Right Grant
- 2008-12-22 SI SI200831404T patent/SI2235059T1/sl unknown
- 2008-12-22 CA CA2958185A patent/CA2958185C/en active Active
- 2008-12-22 CN CN201510633350.6A patent/CN105418762B/zh active Active
- 2008-12-22 HR HRP20150279TT patent/HRP20150279T1/hr unknown
- 2008-12-22 EP EP23178226.9A patent/EP4269443A3/en not_active Withdrawn
- 2008-12-22 PL PL08866130T patent/PL2235059T3/pl unknown
- 2008-12-22 CA CA2703997A patent/CA2703997C/en active Active
- 2008-12-22 HU HUE08866130A patent/HUE024903T2/en unknown
- 2008-12-22 ES ES08866130.1T patent/ES2532461T3/es active Active
- 2008-12-22 PT PT14171372T patent/PT2808343T/pt unknown
- 2008-12-22 CA CA3147069A patent/CA3147069A1/en active Pending
- 2008-12-22 EP EP20203913.7A patent/EP3825329A1/en active Pending
- 2008-12-22 CN CN200880123009.4A patent/CN101910199B/zh active Active
- 2008-12-22 EP EP22169293.2A patent/EP4098661A1/en not_active Withdrawn
- 2008-12-22 HU HUE14171372 patent/HUE044466T2/hu unknown
- 2008-12-22 KR KR1020107013327A patent/KR101616758B1/ko active Active
- 2008-12-22 BR BRPI0821604-5A patent/BRPI0821604B1/pt active IP Right Grant
- 2008-12-22 EP EP19169906.5A patent/EP3575317A1/en active Pending
- 2008-12-22 WO PCT/US2008/088053 patent/WO2009086320A1/en active Application Filing
2010
- 2010-06-17 IL IL206457A patent/IL206457A/en active IP Right Grant
2014
- 2014-05-27 AU AU2014202872A patent/AU2014202872B2/en active Active
- 2014-07-25 RU RU2014131097A patent/RU2700882C2/ru active
- 2014-12-04 IL IL236082A patent/IL236082A0/en active IP Right Grant
2015
- 2015-04-01 JP JP2015075006A patent/JP6043395B2/ja active Active
2016
- 2016-09-29 AU AU2016234983A patent/AU2016234983C1/en active Active
- 2016-11-11 JP JP2016220662A patent/JP2017060497A/ja active Pending
2017
- 2017-11-24 AU AU2017265140A patent/AU2017265140C1/en active Active
2018
- 2018-09-27 JP JP2018181971A patent/JP6678717B2/ja active Active
2019
- 2019-06-12 US US16/439,575 patent/US20200255502A1/en not_active Abandoned
- 2019-07-31 HR HRP20191379TT patent/HRP20191379T8/hr unknown
- 2019-08-06 AU AU2019213332A patent/AU2019213332B2/en active Active
- 2019-08-12 CY CY20191100863T patent/CY1122019T1/el unknown
- 2019-09-04 RU RU2019127861A patent/RU2019127861A/ru unknown
- 2019-12-19 CY CY2019046C patent/CY2019046I2/el unknown
- 2019-12-19 HU HUS1900055C patent/HUS1900055I1/hu unknown
- 2019-12-19 NO NO2019047C patent/NO2019047I1/no unknown
- 2019-12-19 HU HUS1900054C patent/HUS1900054I1/hu unknown
- 2019-12-20 LU LU00142C patent/LUC00142I2/fr unknown
- 2019-12-20 LT LTPA2019019C patent/LTPA2019019I1/lt unknown
- 2019-12-20 LT LTPA2019020C patent/LTC2808343I2/lt unknown
- 2019-12-27 FR FR19C1075C patent/FR19C1075I1/fr active Active
2020
- 2020-02-27 US US16/803,690 patent/US20200262899A1/en active Pending
- 2020-03-17 JP JP2020046564A patent/JP2020120658A/ja active Pending
- 2020-03-25 US US16/830,063 patent/US20210115118A1/en not_active Abandoned
- 2020-10-23 US US17/079,299 patent/US11932685B2/en active Active
2021
- 2021-03-19 JP JP2021045891A patent/JP7051266B2/ja active Active
- 2021-09-23 AU AU2021236525A patent/AU2021236525A1/en not_active Abandoned
- 2021-10-19 JP JP2021171233A patent/JP2022020674A/ja not_active Ceased
2023
- 2023-03-17 JP JP2023043279A patent/JP2023085354A/ja not_active Ceased
2025
- 2025-02-07 AU AU2025200835A patent/AU2025200835A1/en active Pending

Also Published As

Publication number	Publication date
CA3086659A1 (en)	2009-07-09
CN101910199A (zh)	2010-12-08
CN105418762B (zh)	2019-11-05
AU2025200835A1 (en)	2025-02-27
EP3825329A1 (en)	2021-05-26
LTC2808343I2 (lt)	2020-09-10
US20200255502A1 (en)	2020-08-13
CY2019046I1 (el)	2020-05-29
AU2019213332A1 (en)	2019-08-29
LUC00142I2 (no)	2021-07-06
RU2700882C2 (ru)	2019-09-23
LTPA2019020I1 (lt)	2020-01-10
EP2808343B8 (en)	2020-01-15
US20210277095A1 (en)	2021-09-09
CA3147069A1 (en)	2009-07-09
JP5726534B2 (ja)	2015-06-03
SI2235059T1 (sl)	2015-06-30
AU2021236525A1 (en)	2021-10-28
CA2703997C (en)	2017-04-04
IL236082A0 (en)	2015-09-24
ES2532461T3 (es)	2015-03-27
DK2808343T3 (da)	2019-08-19
CA2958185A1 (en)	2009-07-09
IL206457A (en)	2015-03-31
KR101616758B1 (ko)	2016-04-29
JP6043395B2 (ja)	2016-12-14
AU2016234983A1 (en)	2016-10-27
IL206457A0 (en)	2010-12-30
AU2016234983C1 (en)	2019-07-04
PL2235059T3 (pl)	2015-08-31
KR20100099179A (ko)	2010-09-10
WO2009086320A1 (en)	2009-07-09
US20210115118A1 (en)	2021-04-22
RU2529951C2 (ru)	2014-10-10
JP6678717B2 (ja)	2020-04-08
AU2008345242B2 (en)	2014-02-27
DK2235059T3 (en)	2015-03-30
SI2808343T1 (sl)	2019-10-30
BRPI0821604B1 (pt)	2021-09-21
EP4098661A1 (en)	2022-12-07
EP4269443A2 (en)	2023-11-01
AU2014202872A1 (en)	2014-06-19
US11932685B2 (en)	2024-03-19
AU2016234983B2 (en)	2017-08-31
JP2023085354A (ja)	2023-06-20
LUC00142I1 (no)	2019-12-23
HUE024903T2 (en)	2016-02-29
FR19C1075I1 (fr)	2020-02-14
EP2808343B1 (en)	2019-05-15
JP2019022507A (ja)	2019-02-14
HRP20150279T1 (hr)	2015-05-08
US20200262899A1 (en)	2020-08-20
AU2008345242A1 (en)	2009-07-09
HUS1900055I1 (hu)	2020-02-28
AU2017265140B2 (en)	2019-05-23
CN105418762A (zh)	2016-03-23
CN101910199B (zh)	2015-11-25
RU2019127861A (ru)	2021-03-04
EP3575317A1 (en)	2019-12-04
AU2014202872B2 (en)	2016-06-30
CY2019046I2 (el)	2020-05-29
AU2017265140C1 (en)	2021-03-11
HRP20191379T1 (hr)	2019-11-15
EP4269443A3 (en)	2023-12-27
JP7051266B2 (ja)	2022-04-11
PL2808343T3 (pl)	2019-11-29
HUE044466T2 (hu)	2019-10-28
JP2021097714A (ja)	2021-07-01
BR122021010656B1 (pt)	2022-07-19
JP2017060497A (ja)	2017-03-30
EP2808343A1 (en)	2014-12-03
HUS1900054I1 (hu)	2020-02-28
JP2015164920A (ja)	2015-09-17
LT2808343T (lt)	2019-09-10
BRPI0821604A2 (pt)	2015-06-23
JP2011507963A (ja)	2011-03-10
JP2020120658A (ja)	2020-08-13
RU2014131097A (ru)	2016-02-20
LTPA2019019I1 (lt)	2020-01-10
EP2235059A1 (en)	2010-10-06
EP2235059B1 (en)	2015-02-18
AU2019213332B2 (en)	2021-07-29
AU2017265140A1 (en)	2017-12-14
CY1122019T1 (el)	2020-05-29
PT2808343T (pt)	2019-09-04
JP2022020674A (ja)	2022-02-01
ES2742268T3 (es)	2020-02-13
HRP20191379T8 (hr)	2020-02-07
CA2958185C (en)	2020-08-25
CA2703997A1 (en)	2009-07-09
RU2010130851A (ru)	2012-02-10

Publication	Publication Date	Title
DE602008006301D1 (de)	2011-06-01	Koaxialnadelanordnung
BRPI0821573A2 (pt)	2016-08-09	benzofuropirimidonas
ATE501136T1 (de)	2011-03-15	Imidazopyridinone
DE502007001207D1 (de)	2009-09-10	Elektrosaugkopf
DK2159224T3 (da)	2012-08-20	Bromphenylsubstituerede thiazolyldihydropyrimidiner
ATE514696T1 (de)	2011-07-15	Diphenyl-dihydro-imidazopyridinone
DE602008002772D1 (de)	2010-11-11	Polyvinylpyrrolidonpulverzusammensetzungen
DE112008003636A5 (de)	2010-10-21	Mehrzuggruppierer
DE602008000923D1 (de)	2010-05-20	Einzelwaferätzgerät
BRPI0811451A2 (pt)	2014-11-04	Exopolissacarídeo
DE602008000749D1 (de)	2010-04-15	Buschschneider
BRPI0814519A2 (pt)	2014-09-30	Organopolissiloxano
BRPI0812840A2 (pt)	2014-12-09	2-imidazolinas
BRPI0815547A2 (pt)	2015-02-10	Depsipeptídeos cícliocos
BRPI0812994A2 (pt)	2014-12-23	Microbiocidas
AT505058A3 (de)	2008-12-15	Türschliesssystem
DE602008004695D1 (de)	2011-03-10	Katalysatorträgerwabe
DE602008001234D1 (de)	2010-06-24	Bandmaterialzuführvorrichtung
DE602008005950D1 (de)	2011-05-19	Münzvereinzeler
DE602008005589D1 (de)	2011-04-28	Rliganden
DE112008001216A5 (de)	2010-02-04	Magnetronplasmaanlage
DE502008001694D1 (de)	2010-12-16	Mitfahrhubwagen
DE112008003094A5 (de)	2010-08-12	Geomatte
DE602008001674D1 (de)	2010-08-19	Wimpernwickler
DE112008003196A5 (de)	2011-02-03	Handpipettiergerät